electroCore, Inc. (NASDAQ:ECOR) Short Interest Down 12.0% in July

electroCore, Inc. (NASDAQ:ECOR) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 15,400 shares, a decline of 12.0% from the July 15th total of 17,500 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 9,300 shares, the short-interest ratio is currently 1.7 days.

electroCore Price Performance

NASDAQ ECOR traded up $0.05 on Monday, hitting $6.15. The stock had a trading volume of 8,563 shares, compared to its average volume of 11,448. The business’s fifty day moving average price is $6.16 and its 200 day moving average price is $6.41. The stock has a market cap of $36.94 million, a price-to-earnings ratio of -2.16 and a beta of 0.55. electroCore has a 52-week low of $4.50 and a 52-week high of $8.08.

electroCore (NASDAQ:ECOR) last announced its earnings results on Wednesday, August 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. electroCore had a negative return on equity of 219.33% and a negative net margin of 88.12%. The firm had revenue of $6.14 million for the quarter, compared to the consensus estimate of $5.85 million. During the same period in the previous year, the business earned ($1.03) EPS. As a group, sell-side analysts anticipate that electroCore will post -1.38 EPS for the current year.

Insider Activity at electroCore

In other news, CEO Daniel S. Goldberger acquired 38,505 shares of electroCore stock in a transaction on Wednesday, June 5th. The shares were bought at an average cost of $6.43 per share, for a total transaction of $247,587.15. Following the acquisition, the chief executive officer now directly owns 249,565 shares of the company’s stock, valued at approximately $1,604,702.95. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other electroCore news, CEO Daniel S. Goldberger bought 38,505 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were acquired at an average price of $6.43 per share, with a total value of $247,587.15. Following the transaction, the chief executive officer now owns 249,565 shares of the company’s stock, valued at approximately $1,604,702.95. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas J. Errico bought 5,000 shares of the stock in a transaction on Thursday, August 15th. The shares were bought at an average price of $6.12 per share, with a total value of $30,600.00. Following the acquisition, the director now owns 233,818 shares of the company’s stock, valued at $1,430,966.16. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 44,505 shares of company stock worth $284,617. Company insiders own 13.14% of the company’s stock.

Hedge Funds Weigh In On electroCore

Several hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC boosted its stake in electroCore by 49.8% in the 1st quarter. International Assets Investment Management LLC now owns 53,020 shares of the company’s stock worth $324,000 after purchasing an additional 17,620 shares in the last quarter. PFG Investments LLC purchased a new position in shares of electroCore in the first quarter worth $111,000. Finally, Renaissance Technologies LLC lifted its stake in shares of electroCore by 3.4% during the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock worth $442,000 after buying an additional 2,270 shares during the period. Institutional investors and hedge funds own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.